NcXHF

KLIMSTRA ET AL
63. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic
neuroendocrine tumors in Japan. J Gastroenterol. 2010;
45;234-243.
64. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical
features, diagnosis and medical treatment: advances. Best Pract Res
Clin Gastroenterol. 2012;26:737-753.
65. Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors
in neuroendocrine carcinoma: an analysis from the NCCN NET
database. J Clin Oncol. 2012;30 (suppl; abstr 4126).
66. Kulke MH, Shah MH, Benson AB 3rd, et al. Neuroendocrine tumors,
version 1.2015. J Natl Compr Canc Netw. 2015;13:78-108.
67. Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful
marker of neuroendocrine tumors? J Clin Oncol. 2007;25:1967-1973.
68. Fendrich V, Waldmann J, Bartsch DK, et al. Surgical management of
pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6:419-428.
69. Bettini R, Boninsegna L, Mantovani W, et al. Prognostic factors at diagnosis
and value of WHO classifıcation in a mono-institutional series
of 180 non-functioning pancreatic endocrine tumours. Ann Oncol.
2008;19:903-908.
70. Furukori M, Imai K, Karasaki H, et al. Clinicopathological features of
small nonfunctioning pancreatic neuroendocrine tumors. World J
Gastroenterol. 2014;20:17949-17954.
71. Strosberg JR, Cheema A, Kvols LK. Stage I nonfunctioning neuroendocrine
tumors of the pancreas: surgery or surveillance? J Clin Oncol.
2011;29 (suppl; abstr 349).
72. Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic
neuroendocrine tumor metastasis: results from an international
multi-institutional analysis. Ann Surg Oncol. 2010;17:3129-3136.
73. Saxena A, Chua TC, Perera M, et al. Surgical resection of hepatic metastases
from neuroendocrine neoplasms: a systemic review. Surg Oncol.
2012;21:e131-e141.
74. Capurso G, Archibugi L, Delle Fave G. Molecular pathogenesis and
targeted therapy of sporadic pancreatic neuroendocrine tumors.
J Hepatobiliary Pancreat Sci. Epub 2015 Jan 25.
75. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled,
double-blind, prospective, randomized study on the effect of octreotide
LAR in the control of tumor growth in patients with metastatic
neuroendocrine midgut tumors: a report from the PROMID Study
Group. J Clin Oncol. 2009;27:4656-4663.
76. Caplin ME, Pavel M, Ćwikla JB, et al. Lanreotide in metastatic enteropancreatic
neuroendocrine tumors. N Engl J Med. 2014;371:224-233.
77. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the
radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate:
toxicity, effıcacy, and survival. J Clin Oncol. 2008;26:2124-2130.
78. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment
of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:
501-513.
79. Hobday TJ, Qin R, Reidy-Lagunes D, et al. Multicenter phase II trial of
temsirolimus and bevacizumab in pancreatic neuroendocrine tumors.
J Clin Oncol. Epub 2014 Dec 8.
80. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin,
streptozocin-fluorouracil or chlorozotocin in the treatment of advanced
islet-cell carcinoma. N Engl J Med. 1992;326:519-523.
81. Cheng PN, Saltz LB. Failure to confırm major objective antitumor activity
for streptozocin and doxorubicin in the treatment of patients
with advanced islet cell carcinoma. Cancer. 1999;86:944-948.
82. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and
streptozocin in the treatment of patients with locally advanced and
metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:
4762-4771.
83. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine
and temozolomide in patients with metastatic pancreatic endocrine
carcinomas. Cancer. 2011;117:268-275.
84. Ducreux M, Dahah L, Smith D, et al. Bevacizumab combined with
5-FU/streptozocin in patients with progressive metastatic welldifferentiated
pancreatic neuroendocrine tumors (BETTER trial)-A
phase II non-randomised trial. Eur J Cancer. 2014;50:3098-3106.
85. Kennedy A, Bester L, Salem R, et al. Role of hepatic intra-arterial therapies
in metastatic neuroendocrine tumours (NET): guidelines from
the NET-Liver-Metastases Consensus Conference. HPB (Oxford).
2015;17:29-37.
86. Devcic Z, Rosenberg J, Braat AJ, et al. The effıcacy of hepatic 90Y resin
radioembolization for metastatic neuroendocrine tumors: a metaanalysis.
J Nucl Med. 2014;55:1404-1410.
87. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of
small-cell lung cancer in the United States over the last 30 years: analysis
of the surveillance, epidemiologic, and end results database. J Clin
Oncol. 2006;24:4539-4544.
88. Glisson BS, Moran CA. Large-cell neuroendocrine carcinoma: controversies
in diagnosis and treatment. J Natl Compr Canc Netw. 2011;9:
1122-1129.
89. Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy.
Thorac Cardiovasc Surg. 2005;53:168-172.
90. National Comprehensive Cancer Network. Small cell lung cancer guidelines.
version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/sclc.
pdf.
91. Phan AT, Oberg K, Choi J, et al. NANETS consensus guidelines for the
diagnosis and management of neuroendocrine tumors: welldifferentiated
neuroendocrine tumors of the thorax. Pancreas. 2010;
39:784-798.
92. Jänne P, Freidlin B, Saxman S, et al. Twenty-fıve years of clinical research
for patients with limited-stage small cell lung carcinoma in
North America. Cancer. 2002;95:1528-1538.
93. Slotman BJ, van Tinteren H, Pragg JO, et al. Use of thoracic radiotherapy
for extensive stage small-cell lung cancer: a phase 3 randomised
controlled trial. Lancet. 2015;385:36-42.
94. Varlotto JM, Medford-Davis LN, Recht A, et al. Should large cell neuroendocrine
lung carcinoma be classifıed and treated as a small cell
lung cancer of with other large cell carcinomas? J Thorac Oncol. 2011;
6:1050-1058.
95. Aggarwal R, Zhang T, Small EJ, et al. Neuroendocrine prostate cancer:
subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw.
2014;12:719-726.
96. Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why
they teach us essential lessons about prostate cancer. Oncology (Williston
Park). 2014;28:831-838.
97. Beltran H, Tomlins S, Aparicio A, et al. Aggressive variants of castrationresistant
prostate cancer. Clin Cancer Res. 2014;20:2846-2850.
98. Small EJ, Youngren J, Alumkal J, et al. Neuroendocrine prostate cancer
(NEPC) in patients (pts) with metastatic castration resistant prostate
cancer (mCRPC) resistant to abiraterone and enzalutamide: preliminary
results from the SU2C/PCF/AACR west coast prostate cancer
dream team. Ann Oncol. 2014;25 (suppl; 4 abstr 760PD).
99. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer
(NEPC) progressing from conventional prostatic adenocarcinoma:
Factors associated with time to development of NEPC and survival
from NEPC diagnosis-a systematic review and pooled analysis. J Clin
Oncol. 2014;32:3383-3390.
100. Beltran H, Tagawa ST, Park K, et al. Challenges in recognizing
treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;
30:e386-e389.
102 2015 ASCO EDUCATIONAL BOOK | asco.org/edbook